Compare Appian Corp (APPN) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Appian Corp vs Cassava Sciences Inc — how do they compare? Appian Corp trades at $35.5 (market cap $2.55B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Appian Corp is far larger — about 53.4× Cassava Sciences Inc's market cap, and Appian Corp is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| APPN | FLNA | |
|---|---|---|
Market Cap | $2.55B | $47.75M |
Sector | Technology | Health |
52-Week High | $45.64 | $4.64 |
52-Week Low | $18.72 | $0.87 |
Enterprise Value | $2.68B | -$34.93M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Appian (APPN) surged 13.91% to $34.64 following strong Q2 2026 earnings that exceeded expectations, with cloud subscription revenue growing 23% year-over-year. The stock trades near its pivot point of $34 with bullish technical signals from moving averages, though RSI levels suggest potential overbought conditions. Revenue growth has accelerated from $617M in 2024 to $727M in 2025, with the company achieving its first profitable year with $1.23M net income after several years of losses.
Appian demonstrates improving fundamentals with consistent revenue growth and recent profitability, though negative equity and high debt levels present risks. Analyst sentiment is mixed with 31.58% buy ratings but a consensus price target of $32.50 below current levels. The AI-driven workflow platform shows strong enterprise adoption, but investors should weigh growth potential against valuation concerns and competitive pressures in the low-code automation space.
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
